Skip to main content
logo
Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · Real-Time Price · USD
6.26
-0.05 (-0.79%)
Aug 25, 2026, 10:03 AM EDT - Market open

Aclaris Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
8.227.8318.7231.2529.756.76
Revenue Growth
-51.04%-58.19%-40.09%5.03%340.05%4.30%
Gross Profit
-62.28-52.1-30.32-83-60.02-41.77
Operating Income
-85.51-74.08-52.53-114.51-85.15-65.38
Net Income
-75.74-64.92-132.07-88.48-86.91-90.87
Earnings Per Share
-0.59-0.53-1.71-1.27-1.33-1.60
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
170.62151.36203.9181.88229.81225.66
Total Debt
1.852.122.63.52.252.89
Net Cash (Debt)
168.77149.25201.3178.38227.56222.76
Net Cash Growth
-5.46%-25.86%12.85%-21.61%2.15%457.17%
Net Cash Per Share
1.311.222.602.563.493.93

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-62.06-47.11-20.08-78.33-67.57-52.13
Capital Expenditures
-0.12-0.11-0.12-1.31-0.61-0.31
Free Cash Flow
-62.18-47.22-20.2-79.63-68.17-52.44
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
---161.99%-265.60%-201.74%-
Operating Margin
-1040.43%-946.52%-280.59%-366.44%-286.21%-967.08%
Pretax Margin
-921.50%-829.58%-705.48%-284.32%-292.11%-1343.96%
Profit Margin
-921.50%-829.58%-705.48%-283.15%-292.11%-1343.96%
FCF Margin
-756.50%-603.42%-107.89%-254.84%-229.13%-775.65%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
113.0141.6714.182.3835.30131.67